secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001000694-25-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q3 net loss $202M, revenue down to $70M; raises FY2025 revenue guidance
-------------------------------------------------------------------------------

- Total revenue $70M, down 18% YoY from $85M; product sales (Nuvaxovid) $0 vs $38M.
- Net loss $202M vs $121M YoY; includes $97M asset impairment from Maryland site consolidation.
- Cash $778M as of Sep 30, 2025; completed convertible debt refinancing extending maturities to 2031.
- Sanofi milestones $225M YTD; $50M earned on marketing authorization transfers in Q4 2025.
- Maryland site consolidation yields $60M cash proceeds, ~$230M cost savings over 11 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000048/0001000694-25-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000100069425000048/nvax-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001000694-25-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer